A supplemental new drug application (sNDA) seeking approval of WELIREG (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL), has been accepted for priority review by the U.S. Food and Drug Administration (FDA). The sNDA is based on objective response rate (ORR) and duration of response (DOR) data from the Phase 2...